|1st September 2020||Inc. Innoviva,||4,672,897||Open or private purchase||$2.68||$12,499,999.48|
|11th June 2020||Inc. Innoviva,||12,677,490||Open or private purchase||$2.50||$31,693,725.00|
|27th March 2020||Inc. Innoviva,||7,717,661||Open or private purchase||$2.87||$22,149,687.07|
|4th February 2020||Life Sciences Viii, L.P. Frazier||6,360,272||Conversion of derivative||$0.00|
|4th February 2020||Life Sciences Viii, L.P. Frazier||2,099,019||Conversion of derivative||$0.00|
|4th February 2020||Life Sciences Viii, L.P. Frazier||1,074,467||Conversion of derivative||$0.00|
|4th February 2020||Life Sciences Viii, L.P. Frazier||500,000||Open or private purchase||$17.00||$8,500,000.00|
|9th January 2020||Life Sciences Viii, L.P. Frazier||50,000||Open or private sale||$5.00||$250,010.00|
|18th January 2019||Life Sciences Viii, L.P. Frazier||372,439||Open or private purchase||$5.37||$1,999,997.43|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.